Nurix Therapeutics (NRIX) Other Non-Current Assets (2019 - 2026)

Nurix Therapeutics (NRIX) has reported Other Non-Current Assets for 8 consecutive years, with $968000.0 the latest figure, recorded in Q2 2026.

• In Q2 2026, Other Non-Current Assets rose 7.44% year-over-year to $968000.0; the TTM figure through May 2026 stood at $968000.0 (up 7.44% YoY), while the FY2025 annual figure was $7.3 million, up 132.38% from the prior year.
• Other Non-Current Assets was little changed at $968000.0 in Q2 2026 per NRIX's latest filing, from $968000.0 in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $7.3 million in Q4 2025 and bottomed at $901000.0 in Q1 2022.
• Historically, Other Non-Current Assets has averaged $1.4 million across 5 years, with a median of $901000.0 in 2022.
• Annual changes were most pronounced in 2022 — Other Non-Current Assets plunged 67.18% — and 2024, when it jumped 250.61%.
• Nurix Therapeutics' Other Non-Current Assets stood at $901000.0 in 2022, then changed by 0.0% to $901000.0 in 2023, then surged by 250.61% to $3.2 million in 2024, then soared by 132.38% to $7.3 million in 2025, then plunged by 86.81% to $968000.0 in 2026.
• Business Quant data shows NRIX's Other Non-Current Assets at $968000.0 in Q2 2026, $968000.0 in Q1 2026, and $7.3 million in Q4 2025.